Advanced search
Publication Cover
Journal of Medical Economics Volume 19, 2016 - Issue 4
Submit an article Journal homepage
1,601
Views
3
CrossRef citations to date
0
Altmetric
Hematology

Pharmacoeconomics of ruxolitinib therapy in patients with myelofibrosis

Björn VandewalleExigo Consultores, Lisbon, Portugal;Exigo Consultores, Lisbon, Portugal
,
Valeska AndreozziExigo Consultores, Lisbon, Portugal;Exigo Consultores, Lisbon, Portugal
,
João AlmeidaExigo Consultores, Lisbon, Portugal;Exigo Consultores, Lisbon, Portugal
&
Jorge FélixExigo Consultores, Lisbon, Portugal;Exigo Consultores, Lisbon, PortugalCorrespondence[email protected]
Pages 424-431 | Accepted 15 Dec 2015, Published online: 08 Jan 2016

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Monia Marchetti. (2017) Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Review of Pharmacoeconomics & Outcomes Research 17:5, pages 469-480.
Read now
Claire N. Harrison. (2016) JAK inhibitors truly changing the therapeutic paradigm in myelofibrosis. Journal of Medical Economics 19:4, pages 443-444.
Read now

Articles from other publishers (1)

María Teresa Gómez-Casares, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz & Rudi Subirá. (2017) Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. Journal of Health Economics and Outcomes Research 5:2, pages 162-174.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.